Table 6. Univariate analysis of factors in patients with end-of-treatment PET/CT (n = 28).
| Risk Factor | PFS |
OS |
||||
|---|---|---|---|---|---|---|
| Mean (SE) | 95% CI | P | Mean (SE) | 95% CI | P | |
| Sex | ||||||
| Male | 30.24 (5.39) | 19.68–40.81 | 0.545 | 34.58 (4.81) | 25.15–44.01 | 0.376 |
| Female | 39.21 (6.40) | 26.66–51.76 | 46.05 (5.69) | 34.89–57.20 | ||
| Age | ||||||
| ≤60 | 36.72 (4.71) | 27.50–45.95 | 0.190 | 40.86 (4.39) | 32.26–49.46 | 0.934 |
| >60 | 20.33 (12.13) | 0.00–44.11 | 38.67 (9.25) | 20.53–56.80 | ||
| B symptoms | ||||||
| No | 38.71 (6.60) | 25.77–51.66 | 0.562 | 46.88 (5.18) | 36.73–57.03 | 0.236 |
| Yes | 29.42 (5.35) | 18.94–39.91 | 33.16 (4.85) | 23.65–42.67 | ||
| ECOG | ||||||
| <2 | 35.13 (4.72) | 25.88–44.38 | 0.296 | 39.00 (4.58) | 30.03–47.97 | 0.565 |
| ≥2 | 30.70 (7.71) | 15.60–45.80 | 37.30 (6.88) | 23.83–50.77 | ||
| LDH level | ||||||
| ≤245 U/L | 33.39 (5.52) | 22.58–44.21 | 0.813 | 39.30 (5.17) | 29.17–49.44 | 0.652 |
| >245 U/L | 35.35 (6.19) | 23.22–47.49 | 39.28 (5.63) | 28.25–50.31 | ||
| IPI score | ||||||
| 0–1 | 35.25 (4.73) | 25.97–44.53 | 0.356 | 39.08 (4.61) | 30.04–48.11 | 0.616 |
| 2–5 | 31.20 (7.57) | 16.36–46.04 | 37.80 (6.68) | 24.70–50.90 | ||
| KPI score | ||||||
| 0–2 | 39.34 (5.13) | 29.29–49.39 | 0.179 | 46.29 (4.46) | 37.54–55.03 | 0.074 |
| 3–4 | 18.00 (3.99) | 10.19–25.81 | 20.78 (3.29) | 14.33–27.23 | ||
| Ann Arbor Stage | ||||||
| I/II | 33.76 (4.37) | 25.20–42.33 | 0.380 | 37.41 (4.31) | 28.97–45.86 | 0.471 |
| III/IV | 31.67 (6.79) | 18.37–44.97 | 37.41 (6.04) | 25.57–49.24 | ||
| E–PET | ||||||
| Negative | 41.52 (4.94) | 31.83–51.20 | 0.014 | 47.00 (4.13) | 38.91–55.09 | 0.019 |
| Positive | 14.67 (3.95) | 6.92–22.42 | 19.10 (3.45) | 12.33–25.87 | ||
ECOG, Eastern Cooperative Oncology Group; IPI, International Prognostic Index; KPI, Korean prognostic index; E-PET, end-of-treatment PET/CT; PFS, progression-free survival; OS, overall survival.